Guerbet launches a new multi-patient solution, with no compromise on efficiency and patient safety

23.11.2018 08:00

Presented for the first time at the Radiological Society of North America
meeting (RSNA, Chicago, November 25–30, 2018), this solution broadens
Guerbet’s multi-patient range

Villepinte, November 23, 2018 (8:00 CET) - Guerbet, a global specialist in contrast agents and solutions for medical imaging, announced today that the OptiVantage® multi-use injector is now CE-marked. This injector is designed for injecting contrast agents used in X-ray (CT scan) medical examinations.

This new solution includes the tried-and-tested OptiVantage® syringe-based injector, a complete range of associated syringes and disposables (manyFill® day set and secufill® patient line), services and support systems (OptiProtect™).

OptiVantage® multi-use will initially be marketed in EMEA from January 2019, then progressively in other regions of the world (Asia and Latin America).

Existing OptiVantage® customers may benefit from an upgrade to easily implement the new multi-use feature.

Guerbet Group Chief Commercial Officer, Diagnostic Imaging, David Hale declared: “We are delighted to be providing radiology professionals with this new multi-use injection solution, which answers market needs without compromising efficiency and patient safety.”

The market targeted by OptiVantage® multi-use represents over half of all CT procedures worldwide.